[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
[2] Hashibe M, Brennan P, Benhamou S, Castellsague X, Chen C, Curado MP, et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst. 2007;99:777-89.
[3] Jou A, Hess J. Epidemiology and Molecular Biology of Head and Neck Cancer. Oncology Research and Treatment. 2017;40:328-32.
[4] Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. NATURE REVIEWS CANCER. 2011;11:9-22.
[5] Chauhan SS, Kaur J, Kumar M, Matta A, Srivastava G, Alyass A, et al. Prediction of recurrence-free survival using a protein expression-based risk classifier for head and neck cancer. Oncogenesis. 2015;4:e147.
[6] Garcia J, Lopez M, Lopez L, Bague S, Granell E, Quer M, et al. Validation of the pathological classification of lymph node metastasis for head and neck tumors according to the 8th edition of the TNM Classification of Malignant Tumors. ORAL ONCOLOGY. 2017;70:29-33.
[7] Angell H, Galon J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. CURRENT OPINION IN IMMUNOLOGY. 2013;25:261-7.
[8] Mirza AH, Thomas G, Ottensmeier CH, King EV. Importance of the immune system in head and neck cancer. Head & Neck. 2019;41:2789-800.
[9] Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. NATURE MEDICINE. 2015;21:938-45.
[10] Miyauchi S, Kim SS, Pang J, Gold KA, Gutkind JS, Califano JA, et al. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics. CLINICAL CANCER RESEARCH. 2019;25:4211-23.
[11] Azoury SC, Gilmore RC, Shukla V. Molecularly targeted agents and immunotherapy for the treatment of head and neck squamous cell cancer (HNSCC). Discovery Medicine. 2016;21:507-16.
[12] Haddad R, Cohen E, Venkatachalam M, Young K, Singh P, Shaw JW, et al. Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States. JOURNAL OF MEDICAL ECONOMICS. 2020:1-6.
[13] Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. LANCET ONCOLOGY. 2016;17:956-65.
[14] Wang J, Chen X, Tian Y, Zhu G, Qin Y, Chen X, et al. Six-gene signature for predicting survival in patients with head and neck squamous cell carcinoma. Aging (Albany NY). 2020;12:767-83.
[15] She Y, Kong X, Ge Y, Yin P, Liu Z, Chen J, et al. Immune-related gene signature for predicting the prognosis of head and neck squamous cell carcinoma. Cancer Cell International. 2020;20:22.
[16] Yang B, Fu L, Xu S, Xiao J, Li Z, Liu Y. A nomogram based on a gene signature for predicting the prognosis of patients with head and neck squamous cell carcinoma. Int J Biol Markers. 2019;34:309-17.
[17] Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. NUCLEIC ACIDS RESEARCH. 2015;43:e47.
[18] Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY. 2012;16:284-7.
[19] Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. GENOME RESEARCH. 2003;13:2498-504.
[20] Frost HR, Amos CI. Gene set selection via LASSO penalized regression (SLPR). NUCLEIC ACIDS RESEARCH. 2017;45:e114.
[21] Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. INTERNATIONAL JOURNAL OF CANCER. 2005;114:806-16.
[22] Xing L, Guo M, Zhang X, Zhang X, Liu F. A transcriptional metabolic gene-set based prognostic signature is associated with clinical and mutational features in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol. 2020;146:621-30.
[23] Liu C, Yu Z, Huang S, Zhao Q, Sun Z, Fletcher C, et al. Combined identification of three miRNAs in serum as effective diagnostic biomarkers for HNSCC. EBioMedicine. 2019;50:135-43.
[24] Yang B, Shen J, Xu L, Chen Y, Che X, Qu X, et al. Genome-Wide Identification of a Novel Eight-lncRNA Signature to Improve Prognostic Prediction in Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology. 2019;9:898.
[25] Zhao X, Cui L. Development and validation of a m(6)A RNA methylation regulators-based signature for predicting the prognosis of head and neck squamous cell carcinoma. American Journal of Cancer Research. 2019;9:2156-69.
[26] Ferris RL. Immunology and Immunotherapy of Head and Neck Cancer. JOURNAL OF CLINICAL ONCOLOGY. 2015;33:3293-304.
[27] Peluso I, Yarla NS, Ambra R, Pastore G, Perry G. MAPK signalling pathway in cancers: Olive products as cancer preventive and therapeutic agents. SEMINARS IN CANCER BIOLOGY. 2019;56:185-95.
[28] Lee TI, Young RA. Transcriptional regulation and its misregulation in disease. CELL. 2013;152:1237-51.
[29] Barbi J, Pardoll DM, Pan F. Ubiquitin-dependent regulation of Foxp3 and Treg function. IMMUNOLOGICAL REVIEWS. 2015;266:27-45.
[30] Jie HB, Gildener-Leapman N, Li J, Srivastava RM, Gibson SP, Whiteside TL, et al. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer. 2013;109:2629-35.
[31] Chen C, Rowell EA, Thomas RM, Hancock WW, Wells AD. Transcriptional regulation by Foxp3 is associated with direct promoter occupancy and modulation of histone acetylation. JOURNAL OF BIOLOGICAL CHEMISTRY. 2006;281:36828-34.
[32] Shen S, Wang G, Zhang R, Zhao Y, Yu H, Wei Y, et al. Development and validation of an immune gene-set based Prognostic signature in ovarian cancer. EBioMedicine. 2019;40:318-26.
[33] Shen C, Liu J, Wang J, Zhong X, Dong D, Yang X, et al. Development and validation of a prognostic immune-associated gene signature in clear cell renal cell carcinoma. INTERNATIONAL IMMUNOPHARMACOLOGY. 2020;81:106274.
[34] Yang S, Wu Y, Deng Y, Zhou L, Yang P, Zheng Y, et al. Identification of a prognostic immune signature for cervical cancer to predict survival and response to immune checkpoint inhibitors. OncoImmunology. 2019;8:e1659094.
[35] Guo D, Wang M, Shen Z, Zhu J. A new immune signature for survival prediction and immune checkpoint molecules in lung adenocarcinoma. Journal of Translational Medicine. 2020;18:118.
[36] Wang Z, Zhu J, Liu Y, Liu C, Wang W, Chen F, et al. Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma. Journal of Translational Medicine. 2020;18:16-67.
[37] Koneva LA, Zhang Y, Virani S, Hall PB, McHugh JB, Chepeha DB, et al. HPV Integration in HNSCC Correlates with Survival Outcomes, Immune Response Signatures, and Candidate Drivers. MOLECULAR CANCER RESEARCH. 2018;16:90-102.
[38] Han Q, Wang R, Sun C, Jin X, Liu D, Zhao X, et al. Human beta-defensin-1 suppresses tumor migration and invasion and is an independent predictor for survival of oral squamous cell carcinoma patients. PLoS One. 2014;9:e91867.
[39] Pattani KM, Zhang Z, Demokan S, Glazer C, Loyo M, Goodman S, et al. Endothelin receptor type B gene promoter hypermethylation in salivary rinses is independently associated with risk of oral cavity cancer and premalignancy. Cancer Prev Res (Phila). 2010;3:1093-103.
[40] Maia LL, Peterle GT, Dos SM, Trivilin LO, Mendes SO, de Oliveira MM, et al. JMJD1A, H3K9me1, H3K9me2 and ADM expression as prognostic markers in oral and oropharyngeal squamous cell carcinoma. PLoS One. 2018;13:e194884.
[41] Gao J, Ulekleiv CH, Halstensen TS. Epidermal growth factor (EGF) receptor-ligand based molecular staging predicts prognosis in head and neck squamous cell carcinoma partly due to deregulated EGF- induced amphiregulin expression. J Exp Clin Cancer Res. 2016;35:151.
[42] Katase N, Gunduz M, Beder LB, Gunduz E, Al SAM, Tamamura R, et al. Frequent allelic loss of Dkk-1 locus (10q11.2) is related with low distant metastasis and better prognosis in head and neck squamous cell carcinomas. CANCER INVESTIGATION. 2010;28:103-10.
[43] Meng Y, Yu F. Long noncoding RNA FAM3D-AS1 inhibits development of colorectal cancer through NF-kappaB signaling pathway. Biosci Rep. 2019;39.
[44] Nagy A, Schally AV. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers. BIOLOGY OF REPRODUCTION. 2005;73:851-9.
[45] Li T, Qin Y, Zhen Z, Shen H, Cong T, Schiferle E, et al. Long non-coding RNA HOTAIR/microRNA-206 sponge regulates STC2 and further influences cell biological functions in head and neck squamous cell carcinoma. Cell Prolif. 2019;52:e12651.
[46] Johnston AJ, Murphy KT, Jenkinson L, Laine D, Emmrich K, Faou P, et al. Targeting of Fn14 Prevents Cancer-Induced Cachexia and Prolongs Survival. CELL. 2015;162:1365-78.
[47] Mocellin S, Nitti D. CTLA-4 blockade and the renaissance of cancer immunotherapy. Biochim Biophys Acta. 2013;1836:187-96.
[48] Shang B, Liu Y, Jiang SJ, Liu Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep. 2015;5:15179.
[49] Seminerio I, Descamps G, Dupont S, de Marrez L, Laigle JA, Lechien JR, et al. Infiltration of FoxP3+ Regulatory T Cells is a Strong and Independent Prognostic Factor in Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2019;11.
[50] Kumar AT, Knops A, Swendseid B, Martinez-Outschoom U, Harshyne L, Philp N, et al. Prognostic Significance of Tumor-Associated Macrophage Content in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis. Frontiers in Oncology. 2019;9:656.
[51] Nishino M, Ramaiya NH, Hatabu H, Hodi FS. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nature Reviews Clinical Oncology. 2017;14:655-68.
[52] Chen SW, Li SH, Shi DB, Jiang WM, Song M, Yang AK, et al. Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance. Int J Biol Markers. 2019;34:398-405.
[53] Schneider S, Kadletz L, Wiebringhaus R, Kenner L, Selzer E, Fureder T, et al. PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome. HISTOPATHOLOGY. 2018;73:573-84.
[54] Joly S, Compton LM, Pujol C, Kurago ZB, Guthmiller JM. Loss of human beta-defensin 1, 2, and 3 expression in oral squamous cell carcinoma. Oral Microbiol Immunol. 2009;24:353-60.
[55] Canel M, Secades P, Garzon-Arango M, Allonca E, Suarez C, Serrels A, et al. Involvement of focal adhesion kinase in cellular invasion of head and neck squamous cell carcinomas via regulation of MMP-2 expression. Br J Cancer. 2008;98:1274-84.
[56] Hayes AJ, Melrose J. Keratan Sulphate in the Tumour Environment. Advances in Experimental Medicine and Biology. 2020;1245:39-66.
[57] Iida J, Dorchak J, Clancy R, Slavik J, Ellsworth R, Katagiri Y, et al. Role for chondroitin sulfate glycosaminoglycan in NEDD9-mediated breast cancer cell growth. EXPERIMENTAL CELL RESEARCH. 2015;330:358-70.